Radvanyi F - Search Results

1

Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients.

Mertens LS, Claps F, Mayr R, Bostrom PJ, Shariat SF, Zwarthoff EC, Boormans JL, Abas C, van Leenders GJLH, Götz S, Hippe K, Bertz S, Neuzillet Y, Sanders J, Broeks A, Peters D, van der Heijden MS, Jewett MAS, Stöhr R, Zlotta AR, Eckstein M, Soorojebally Y, van der Schoot DKE, Wullich B, Burger M, Otto W, Radvanyi F, Sirab N, Pouessel D, van der Kwast TH, Hartmann A, Lotan Y, Allory Y, Zuiverloon TCM, van Rhijn BWG. Mertens LS, et al. Among authors: radvanyi f. Urol Oncol. 2022 Mar;40(3):110.e1-110.e9. doi: 10.1016/j.urolonc.2021.10.010. Epub 2021 Dec 11. Urol Oncol. 2022. PMID: 34906411 Free article.

2

The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate.

van Rhijn BW, Lurkin I, Radvanyi F, Kirkels WJ, van der Kwast TH, Zwarthoff EC. van Rhijn BW, et al. Among authors: radvanyi f. Cancer Res. 2001 Feb 15;61(4):1265-8. Cancer Res. 2001. PMID: 11245416

3

Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors.

Billerey C, Chopin D, Aubriot-Lorton MH, Ricol D, Gil Diez de Medina S, Van Rhijn B, Bralet MP, Lefrere-Belda MA, Lahaye JB, Abbou CC, Bonaventure J, Zafrani ES, van der Kwast T, Thiery JP, Radvanyi F. Billerey C, et al. Among authors: radvanyi f. Am J Pathol. 2001 Jun;158(6):1955-9. doi: 10.1016/S0002-9440(10)64665-2. Am J Pathol. 2001. PMID: 11395371 Free PMC article.

4

Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders.

van Rhijn BW, van Tilborg AA, Lurkin I, Bonaventure J, de Vries A, Thiery JP, van der Kwast TH, Zwarthoff EC, Radvanyi F. van Rhijn BW, et al. Among authors: radvanyi f. Eur J Hum Genet. 2002 Dec;10(12):819-24. doi: 10.1038/sj.ejhg.5200883. Eur J Hum Genet. 2002. PMID: 12461689

5

Combined microsatellite and FGFR3 mutation analysis enables a highly sensitive detection of urothelial cell carcinoma in voided urine.

van Rhijn BW, Lurkin I, Chopin DK, Kirkels WJ, Thiery JP, van der Kwast TH, Radvanyi F, Zwarthoff EC. van Rhijn BW, et al. Among authors: radvanyi f. Clin Cancer Res. 2003 Jan;9(1):257-63. Clin Cancer Res. 2003. PMID: 12538478

6

Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome.

van Rhijn BW, Vis AN, van der Kwast TH, Kirkels WJ, Radvanyi F, Ooms EC, Chopin DK, Boevé ER, Jöbsis AC, Zwarthoff EC. van Rhijn BW, et al. Among authors: radvanyi f. J Clin Oncol. 2003 May 15;21(10):1912-21. doi: 10.1200/JCO.2003.05.073. J Clin Oncol. 2003. PMID: 12743143

7

Phospho-Akt pathway activation and inhibition depends on N-cadherin or phospho-EGFR expression in invasive human bladder cancer cell lines.

Wallerand H, Cai Y, Wainberg ZA, Garraway I, Lascombe I, Nicolle G, Thiery JP, Bittard H, Radvanyi F, Reiter RR. Wallerand H, et al. Among authors: radvanyi f. Urol Oncol. 2010 Mar-Apr;28(2):180-8. doi: 10.1016/j.urolonc.2008.09.041. Epub 2008 Dec 12. Urol Oncol. 2010. PMID: 19070520

8

Occupational exposure to polycyclic aromatic hydrocarbons influenced neither the frequency nor the spectrum of FGFR3 mutations in bladder urothelial carcinoma.

Bakkar AA, Allory Y, Iwatsubo Y, de Medina SG, Maille P, Khreich N, Riou A, Leroy K, Vordos D, Abbou CC, Andujar P, Billebaud T, Chammings S, Conso F, De La Taille A, Fontaine E, Gattegno B, Ravery V, Sibony M, Radvanyi F, Chopin DK, Pairon JC. Bakkar AA, et al. Among authors: radvanyi f. Mol Carcinog. 2010 Jan;49(1):25-31. doi: 10.1002/mc.20573. Mol Carcinog. 2010. PMID: 19722178

9

Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer.

van Rhijn BW, Zuiverloon TC, Vis AN, Radvanyi F, van Leenders GJ, Ooms BC, Kirkels WJ, Lockwood GA, Boevé ER, Jöbsis AC, Zwarthoff EC, van der Kwast TH. van Rhijn BW, et al. Among authors: radvanyi f. Eur Urol. 2010 Sep;58(3):433-41. doi: 10.1016/j.eururo.2010.05.043. Epub 2010 Jun 9. Eur Urol. 2010. PMID: 20646825

10

A novel epigenetic phenotype associated with the most aggressive pathway of bladder tumor progression.

Vallot C, Stransky N, Bernard-Pierrot I, Hérault A, Zucman-Rossi J, Chapeaublanc E, Vordos D, Laplanche A, Benhamou S, Lebret T, Southgate J, Allory Y, Radvanyi F. Vallot C, et al. Among authors: radvanyi f. J Natl Cancer Inst. 2011 Jan 5;103(1):47-60. doi: 10.1093/jnci/djq470. Epub 2010 Dec 20. J Natl Cancer Inst. 2011. PMID: 21173382 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

179 results

Search Page

Filters